A prospective, multicenter, randomized, double-blind, pilot study to evaluate the safety, the efficacy, the tolerability, and the emergence of resistant gram-negative microorganisms in the bowel in elderly patients with serious community-acquired bacterial pneumonia treated with a short regimen fo ertapenem versus high-dose levofloxacin.
Latest Information Update: 14 Apr 2022
At a glance
- Drugs Ertapenem (Primary) ; Levofloxacin
- Indications Community-acquired pneumonia; Gram-negative infections
- Focus Therapeutic Use
- Sponsors Merck Sharp & Dohme
Most Recent Events
- 14 Apr 2022 New trial record